CA3091613A1 - Anti-angiopoietin-2 antibodies and uses thereof - Google Patents

Anti-angiopoietin-2 antibodies and uses thereof Download PDF

Info

Publication number
CA3091613A1
CA3091613A1 CA3091613A CA3091613A CA3091613A1 CA 3091613 A1 CA3091613 A1 CA 3091613A1 CA 3091613 A CA3091613 A CA 3091613A CA 3091613 A CA3091613 A CA 3091613A CA 3091613 A1 CA3091613 A1 CA 3091613A1
Authority
CA
Canada
Prior art keywords
antibody
seq
antigen
ang2
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3091613A
Other languages
English (en)
French (fr)
Inventor
Gou Young Koh
Jeomil BAE
Mi Jeong Kim
Jin-Sung Park
Su Jin Seo
Jaeryung KIM
Jang Ryul Park
Pilhan KIM
Wangyuhl OH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Advanced Institute of Science and Technology
Institute for Basic Science
Original Assignee
Korea Advanced Institute of Science and Technology
Institute for Basic Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Advanced Institute of Science and Technology, Institute for Basic Science filed Critical Korea Advanced Institute of Science and Technology
Priority claimed from PCT/KR2019/001983 external-priority patent/WO2019164219A1/en
Publication of CA3091613A1 publication Critical patent/CA3091613A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3091613A 2018-02-20 2019-02-19 Anti-angiopoietin-2 antibodies and uses thereof Pending CA3091613A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862633038P 2018-02-20 2018-02-20
US62/633,038 2018-02-20
KR1020190018769A KR102497171B1 (ko) 2018-02-20 2019-02-18 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
KR10-2019-0018769 2019-02-18
PCT/KR2019/001983 WO2019164219A1 (en) 2018-02-20 2019-02-19 Anti-angiopoietin-2 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CA3091613A1 true CA3091613A1 (en) 2019-08-29

Family

ID=67775161

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3091613A Pending CA3091613A1 (en) 2018-02-20 2019-02-19 Anti-angiopoietin-2 antibodies and uses thereof

Country Status (8)

Country Link
US (2) US11498962B2 (cg-RX-API-DMAC7.html)
EP (1) EP3755714A4 (cg-RX-API-DMAC7.html)
JP (2) JP7366068B2 (cg-RX-API-DMAC7.html)
KR (1) KR102497171B1 (cg-RX-API-DMAC7.html)
CN (1) CN111741975B (cg-RX-API-DMAC7.html)
AU (1) AU2019224694B2 (cg-RX-API-DMAC7.html)
CA (1) CA3091613A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020008663A (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4201957A4 (en) * 2020-08-19 2025-01-22 Pharmabcine Inc. MODIFIED ANTIBODY AND PROCESS FOR PRODUCTION THEREOF

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102497171B1 (ko) 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
WO2022005171A1 (ko) * 2020-06-30 2022-01-06 삼성전자 주식회사 항-ang2 항체를 포함하는 코로나바이러스 감염증을 치료하기 위한 조성물 및 그의 용도
CN116472285A (zh) * 2020-08-07 2023-07-21 南京金斯瑞生物科技有限公司 针对人血管生成素-2的抗体及其用途
EP4328242A4 (en) * 2021-04-23 2025-07-16 Neortesbio Inc ANTIBODY SPECIFICALLY BINDING TO ANGIOPOIETIN-2 OR FRAGMENT THEREOF
KR102459211B1 (ko) * 2021-04-23 2022-10-26 (주)니오테스바이오 안지오포이에틴-2에 특이적으로 결합하는 항체, 또는 이의 단편
KR20250128899A (ko) * 2024-02-20 2025-08-28 주식회사 맵틱스 Tie2 및 VEGF에 특이적으로 결합하는 이중 특이적 항체 및 이의 용도
WO2025186364A1 (en) 2024-03-06 2025-09-12 Jeansson Marie Angpt2-targeting antibodies for use in the treatment of fibrotic diseases, particularly kidney disease(s), disorder(s) or injury associated with kidney fibrosis
CN121231772B (zh) * 2025-12-02 2026-03-17 武汉市金银潭医院(武汉市传染病医院) 抗体夹心法检测猴痘病毒a29l蛋白的试剂或试剂盒及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
ZA200705695B (en) 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
US8980268B2 (en) * 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EP3415533A1 (en) 2011-08-19 2018-12-19 Regeneron Pharmaceuticals, Inc. Anti-tie2 antibodies uses thereof
US9902767B2 (en) * 2013-07-29 2018-02-27 Samsung Electronics Co., Ltd. Method of blocking vascular leakage using an anti-ANG2 antibody
KR102146845B1 (ko) 2013-07-30 2020-08-21 삼성전자주식회사 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
US9994632B2 (en) 2014-05-26 2018-06-12 Samsung Electronics Co., Ltd. Humanized or affinity-matured anti Ang-2 antibody and uses thereof
WO2016075035A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anti-ang2 antibodies and methods of use
KR102497171B1 (ko) 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4201957A4 (en) * 2020-08-19 2025-01-22 Pharmabcine Inc. MODIFIED ANTIBODY AND PROCESS FOR PRODUCTION THEREOF
AU2021326709B2 (en) * 2020-08-19 2025-06-26 Pharmabcine Inc. Modified antibody and method for manufacturing same

Also Published As

Publication number Publication date
AU2019224694A1 (en) 2020-08-06
EP3755714A1 (en) 2020-12-30
JP7366068B2 (ja) 2023-10-20
AU2019224694B2 (en) 2025-09-04
KR20190100060A (ko) 2019-08-28
US20230272057A1 (en) 2023-08-31
KR102497171B1 (ko) 2023-02-08
US20210079083A1 (en) 2021-03-18
EP3755714A4 (en) 2022-02-16
CN111741975A (zh) 2020-10-02
JP2024009914A (ja) 2024-01-23
CN111741975B (zh) 2025-02-18
US11498962B2 (en) 2022-11-15
MX2020008663A (es) 2021-02-09
US12331106B2 (en) 2025-06-17
JP2021514670A (ja) 2021-06-17

Similar Documents

Publication Publication Date Title
US12331106B2 (en) Anti-angiopoietin-2 antibodies that induce Tie2 activation
JP6892431B2 (ja) 癌治療用のaxl特異的抗体−薬物コンジュゲート
US10519247B2 (en) Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
US20250011438A1 (en) Antibody Binding to Tie2 and Use Thereof
CA3178855A1 (en) Anti-claudin18.2 antibody and use thereof
IL296633A (en) Antibodies that bind axl
CA2955947A1 (en) Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
WO2019164219A1 (en) Anti-angiopoietin-2 antibodies and uses thereof
JP7826279B2 (ja) 抗ベータセルリン抗体、その断片、及び多重特異性結合分子
WO2022068809A1 (zh) 抗cd3抗体以及其用途
HK40130178A (en) Antibody binding to tie2 and use thereof
US12617848B2 (en) Methods of treating ocular pathologies using bifunctional molecules that target growth factors
KR20240056422A (ko) 인간 안지오포이에틴-2에 특이적으로 결합하는 제1 항원 결합 부위를 포함하는 이중특이적 항체 및 그 응용
WO2024092263A2 (en) Anti-adam10 antibodies and uses in treatment of cancer
HK40118737A (en) Vegf and tie2-binding fusion protein and uses thereof
EA051443B1 (ru) Антитела к бетацеллюлину, их фрагменты и мультиспецифические связывающие молекулы

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240216

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250210

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250210

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250210

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250704

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251104

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251231

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251231

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260209